Maze Therapeutics, Inc. (MAZE) Stock Price & Analysis
Maze Therapeutics, Inc. (MAZE) rose 1.48% to USD 23.93 as of June 10, 2026 at 04:05 UTC, according to Nexqual real-time market data.
MAZE last closed at USD 23.58; the session ranged USD 22.92–24.18 on volume of 670,851 shares. Market capitalization is $1.32B, with a 52-week range of USD 9.83–53.65 (NGM). Source: Nexqual, June 10, 2026 at 04:05 UTC.
Key Statistics (as of June 10, 2026 at 04:05 UTC)
| Price | USD 23.93 |
|---|---|
| Change | ▲ 1.48% (up) |
| Previous Close | USD 23.58 |
| Open | USD 23.85 |
| Day Range | USD 22.92 – 24.18 |
| 52-Week Range | USD 9.83 – 53.65 |
| Volume | 670,851 shares |
| Market Cap | $1.32B |
| Exchange | NGM |
Technical Analysis (MAZE)
Nexqual's technical model rates MAZE "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.74 (neutral) |
| vs SMA50 | Below (USD 26.54) |
| MACD | -0.9 (negative) |
Analyst Ratings (MAZE)
Wall Street analysts rate MAZE "None" based on 11 analysts, with a mean price target of USD 62.55 (range USD 46–110), per Nexqual as of June 10, 2026 at 04:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 62.55 |
| High Target | USD 110 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (MAZE)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $1.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.65 vs est -0.69 ▲ beat |
| 2025-09-30 | USD -0.66 vs est -0.69 ▲ beat |
| 2025-06-30 | USD -0.77 vs est -1.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Financials & Fundamentals (MAZE)
| Total Revenue | $20.00M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -132.76% |
| Profit Margin | +0.00% |
| ROE | -38.67% |
| Debt / Equity | 17.92 |
| Current Ratio | 17.88 |
| Total Cash | $352.38M |
| Total Debt | $61.22M |
| Free Cash Flow | $-81.70M |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Financial Health Score (MAZE)
Nexqual rates Maze Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:05 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $352M cash vs $61M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$122M |
| Efficiency | Critical — ROE -39%, ROA -22.3% |
Ownership (MAZE)
| Insider Ownership | +1.46% |
|---|---|
| Institutional Ownership | +95.46% |
| Shares Outstanding | 55.35M |
| Float | 37.19M |
| Short % of Float | +7.93% |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Leadership (MAZE)
Maze Therapeutics, Inc. is led by Jason V. Coloma M.B.A., M.P.H. (age 49), CEO & Director, per Nexqual as of June 10, 2026 at 04:05 UTC.
| CEO & Director | Jason V. Coloma M.B.A., M.P.H. (age 49) |
|---|---|
| CFO & Principal Accounting Officer | Misbah Tahir (age 50) |
| President of Research & Development and Chief Medical Officer | Harold S. Bernstein (age 65) |
| Vice President of R & D Infrastructure and Operations | Vipin Vijayakumar |
| Senior Vice President of Human Resources | Matt Krause |
Major Backers & Investors (MAZE)
Notable institutional backers of Maze Therapeutics, Inc. include Frazier Life Sciences Management, L.P. , TRV GP IV, LLC, Arch Venture Management, Llc, according to Nexqual as of June 10, 2026 at 04:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 8.25% |
| TRV GP IV, LLC | 8.08% |
| Arch Venture Management, Llc | 7.44% |
| Deep Track Capital, Lp | 6.28% |
| Janus Henderson Group PLC | 5.17% |
| Paradigm Biocapital Advisors LP | 4.96% |
| a16z Capital Management, L.L.C. | 3.08% |
| Venrock Adviser, LLC | 2.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.89% |
| Vanguard Group | 5.11% |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
From Maze Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
- Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
- The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
- It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | USD 33.69 | ▼ 4.75% |
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| RAPP | Rapport Therapeutics, Inc. | USD 35.84 | ▼ 0.72% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| DNTH | Dianthus Therapeutics, Inc. | USD 84.57 | ▲ 5.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:05 UTC. This page is informational and not investment advice.